In August 2018, the U.S. Food and Drug Administration published a warning for physicians, patients, and the public alerting that some type 2 diabetes patients who started treatment with an SGLT2 inhibitor medication were diagnosed with a serious flesh-eating infection that attacks genital and anal tissues. Unfortunately, all SGLT2 inhibitor medications approved by the FDA … [Read more...]

A flesh-eating bacterial infection that destroys and decays genital tissue has been associated with the type 2 diabetes drugs classified as SGLT2 inhibitors. Patients with type 2 diabetes who start treatment with common SGLT2 inhibitors such as Jardiance and Farxiga who develop this serious and rapidly progressing infection must seek medical treatment immediately, as this … [Read more...]